Drug Profile
Research programme: diabetes therapy - Napo Pharmaceuticals/Piramal Life Sciences
Latest Information Update: 13 Dec 2017
Price :
$50
*
At a glance
- Originator Napo Pharmaceuticals; Nicholas Piramal India Limited
- Developer Piramal Healthcare
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Diabetes mellitus
Most Recent Events
- 16 Dec 2008 Discontinued - Preclinical for Diabetes mellitus in India (unspecified route)
- 20 May 2008 Preclinical development is ongoing
- 22 Jan 2007 Preclinical trials in Diabetes mellitus in India (unspecified route)